Genentech R&D honcho heads to Rockefeller U.

Genentech's No. 2 R&D exec--Marc Tessier-Lavigne--is leaving his post to take the helm at Rockefeller University, home to some of the world's premier biomedical researchers. Tessier-Lavigne's move to become the first person from the biopharma industry to be named president of Rockefeller--a prestigious position by any standard--inevitably triggered fresh questions from the New York Times' Andrew Pollack about the brain drain from Genentech in the wake of the Roche takeover. But Tessier-Lavigne says he wasn't fleeing Roche management. "Of the top leadership in research, I'm the first person to leave and it has nothing to do with the merger," he tells the Times. "I wasn't looking to move away. In fact, this is probably the only job that could have lured me away from Genentech." Rockefeller release |  Story

Suggested Articles

Barely two years after paying up $263 million for the ex-Asia rights to BeiGene’s tislelizumab, Celgene is bowing out—to the tune of $150 million.

A University of Pennsylvania team discovered that a protein called TOX helps determine the fate of exhausted T cells in cancer and other diseases.

AstraZeneca is set to spend $630 million on R&D in South Korea over the next five years as part of a wider cooperative agreement.